Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Maravai LifeSciences (NASDAQ:MRVI) but lowered the price target from $12 to $11.

November 09, 2023 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Maravai LifeSciences but lowered the price target from $12 to $11.
The news is directly about Maravai LifeSciences. While the Overweight rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term stock price. However, the impact is not necessarily negative as the Overweight rating suggests that the analyst still sees potential in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100